PHILADELPHIA, Nov. 21, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) ("Hemispherx" or the "Company") announced today that it will be presenting at the 9th annual LD Micro Main Event being held on December 6-8, 2016 at the Luxe Sunset Boulevard Hotel in Los Angeles, CA. Thomas Equels, M.S., J.D., Hemispherx's chief executive officer, will be presenting at the conference, and will be available to participate in one-on-one meetings with investors who are registered to attend the conference. Details for the presentation are as follows: Date: Tuesday, December 6, 2016 Time: 9:30 a.m. PSTLocation: Track 3 About LD Micro LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. What started out as a newsletter highlighting unique companies has transformed into an event platform hosting several influential conferences annually (Invitational, Summit, and Main Event). In 2015, LDM launched the first pure microcap index (the LDMi) to exclusively provide intraday information on the entire sector. LD will continue to provide valuable tools for the benefit of everyone in the small and microcap universe.For those interested in attending, please contact David Scher at email@example.com or visit www.ldmicro.com/events for more information. About Hemispherx Biopharma Hemispherx Biopharma, Inc. is an advanced specialty pharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherx's flagship products include Alferon N Injection ® and the experimental therapeutics Rintatolimod® (tradenames Ampligen ® or Rintamod ®) and Alferon ® LDO. Rintatolimod is an experimental RNA nucleic acid being developed for globally important debilitating diseases and disorders of the immune system, including Chronic Fatigue Syndrome. Hemispherx's platform technology includes components for potential treatment of various severely debilitating and life threatening diseases. Because both Rintatolimod and Alferon ® LDO are experimental in nature, they are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials. Hemispherx has patents comprising its core intellectual property estate and a fully commercialized product (Alferon N Injection ®), approved for sale in the U.S. and Argentina. The FDA approval of Alferon N Injection ® is limited to the treatment of refractory or recurrent external genital warts in patients 18 years of age or older. The Company's Alferon N ® approval in Argentina includes the use of Alferon N Injection ® (under the pending brand name "Naturaferon") for use in any patients who fail or become intolerant to recombinant interferon, including patients with chronic active hepatitis C infection. Rintamod® has received approval in the Argentine Republic to treat severe cases of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). It will be marketed by GP Pharm, Hemispherx's commercial partner in Latin America. The Company wholly owns and exclusively operates a GMP certified manufacturing facility in the United States for commercial products. For more information please visit www.hemispherx.net.